Industry experts are due to discuss the treatment of chronic pain, migraine and muscle spasms this week via an online seminar hosted by TorreyPines Therapeutics.

On June 25th, physicians will debate the potential of treating chronic pain by targeting glutamate receptors in the central nervous system and in doing so inhibit the neurotransmitter glutamate.

Chief executive officer and president of TorreyPines Therapeutics company Dr Neil Kurtz, said: "There's a growing body of scientific and clinical evidence that supports the further development of drugs that block the glutamate cascade.

"As the American Headache Society prepares to kick off its 50th Annual Scientific Meeting, we want to provide patients as well as the medical community with industry experts' perspectives as to what is clearly a promising approach for the treatment of migraine and other conditions."

New data presented at the IBC International Conference on Migraine confirmed that a treatment for migraine named Zomig is effective in improving quality of life for migraine sufferers.

According to research, migraine is the most common neurological condition in the developed world, and affects ten to 15 per cent of the global population.

Participants can register for the webinar via http://www.torreypinestherapeutics.com/home.phpLogin and visit the Migraine Knowledge CentreLogin and visit the Opioids and Pain Management Knowledge Centre

• Opioids 'could exacerbate pain' 22/08/08
• High use of complementary methods in cancer survivors, study finds 04/08/08
• Ineffectiveness of infant pain assessment 'cause for concern' 24/06/08
• Shorter self-management programmes 'better for chronic pain' 13/06/08
• Ideal treatment of chronic pain remains uncertain 06/06/08